Wondering if Akeso is still a smart buy after its big run up, or if the best days are already priced in? You are not alone. That is exactly what we are going to unpack. The stock has cooled slightly ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL ...
WKBN Youngstown on MSN
Health care center reaches goal of 1,000 gifts for seniors
The “Gifting for Seniors” drive has been a yearly holiday event since 2020, but this is the most presents the program has ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific ...
Akeso, Inc. (9926.HK) (Akeso or the Company) announced that at the 2025 ESMO Asia Congress, updated results from the pivotal ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
TipRanks on MSN
Akeso’s innovative drugs included in China’s 2025 NRDL
The latest announcement is out from Akeso, Inc. ( (HK:9926) ).
Evercore 8th Annual Healthcare Conference December 3, 2025 2:10 PM ESTCompany ParticipantsDave Gancarz - Chief ...
EAST LIVERPOOL, Ohio (MyValleyTributes) – Fonda R. Moffett, age 63, of East Liverpool, passed away on Friday, December 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback